Submitted by Anonymous (not verified) on 19 September 2024 - 10:40
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0383/2023
Source: